Acute tacrolimus toxicity in a non-transplant patient

Ayrn D. O'Connor, Daniel Rusyniak, James Mowry

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Introduction. Tacrolimus is an immunosuppressant widely used in recipients of solid organ transplants to prevent rejection. Toxicity is usually reported in transplant patients. We report the first case of tacrolimus toxicity in a non-transplant patient. Case report. A 42 year-old, 48 kg woman complained of neck pain following a motor vehicle collision and was admitted for observation. On examination, her pulse was 112 beats/minute and her blood pressure 188/134 mmHg. Because the hypertension and tachycardia might be ethanol withdrawal, she was admitted and treated with multivitamins, folate, and thiamine in her maintenance fluids. She was discharged after 4 days in hospital. The day after her discharge, she was asked to return after it was discovered that she had inadvertently received tacrolimus (total of 400 mg) instead of thiamine. She was admitted with non-oliguric renal failure and metabolic acidosis. A tacrolimus concentration 27 hours after her last exposure was 96.8 ng/mL (therapeutic 5 to 20 ng/mL). Treatment was supportive and she was discharged after 4 days without sequellae. Discussion. Our patient's tacrolimus dose was 2.1 mg/kg/day for 4 days (therapeutic 0.03 to 0.05 mg/kg/day). Her tacrolimus elimination half-life was 16.5 hours, compared to a mean half-life in healthy volunteers of 34.2 ± 7.7 hours. Conclusion. Clinical toxicity, similar to that seen in transplant patients, can develop in non-transplant patients following intravenous administration of supra-therapeutic doses of tacrolimus.

Original languageEnglish
Pages (from-to)838-840
Number of pages3
JournalClinical Toxicology
Volume46
Issue number9
DOIs
StatePublished - Nov 2008

Fingerprint

Tacrolimus
Toxicity
Transplants
Thiamine
Half-Life
Neck Pain
Blood pressure
Motor Vehicles
Therapeutics
Immunosuppressive Agents
Acidosis
Folic Acid
Tachycardia
Intravenous Administration
Renal Insufficiency
Healthy Volunteers
Ethanol
Maintenance
Observation
Blood Pressure

Keywords

  • Acid-base disorders
  • Acute renal failure
  • Dispensing error
  • Toxicity

ASJC Scopus subject areas

  • Toxicology

Cite this

Acute tacrolimus toxicity in a non-transplant patient. / O'Connor, Ayrn D.; Rusyniak, Daniel; Mowry, James.

In: Clinical Toxicology, Vol. 46, No. 9, 11.2008, p. 838-840.

Research output: Contribution to journalArticle

O'Connor, Ayrn D. ; Rusyniak, Daniel ; Mowry, James. / Acute tacrolimus toxicity in a non-transplant patient. In: Clinical Toxicology. 2008 ; Vol. 46, No. 9. pp. 838-840.
@article{a33460913b1f434a83a7919f55649907,
title = "Acute tacrolimus toxicity in a non-transplant patient",
abstract = "Introduction. Tacrolimus is an immunosuppressant widely used in recipients of solid organ transplants to prevent rejection. Toxicity is usually reported in transplant patients. We report the first case of tacrolimus toxicity in a non-transplant patient. Case report. A 42 year-old, 48 kg woman complained of neck pain following a motor vehicle collision and was admitted for observation. On examination, her pulse was 112 beats/minute and her blood pressure 188/134 mmHg. Because the hypertension and tachycardia might be ethanol withdrawal, she was admitted and treated with multivitamins, folate, and thiamine in her maintenance fluids. She was discharged after 4 days in hospital. The day after her discharge, she was asked to return after it was discovered that she had inadvertently received tacrolimus (total of 400 mg) instead of thiamine. She was admitted with non-oliguric renal failure and metabolic acidosis. A tacrolimus concentration 27 hours after her last exposure was 96.8 ng/mL (therapeutic 5 to 20 ng/mL). Treatment was supportive and she was discharged after 4 days without sequellae. Discussion. Our patient's tacrolimus dose was 2.1 mg/kg/day for 4 days (therapeutic 0.03 to 0.05 mg/kg/day). Her tacrolimus elimination half-life was 16.5 hours, compared to a mean half-life in healthy volunteers of 34.2 ± 7.7 hours. Conclusion. Clinical toxicity, similar to that seen in transplant patients, can develop in non-transplant patients following intravenous administration of supra-therapeutic doses of tacrolimus.",
keywords = "Acid-base disorders, Acute renal failure, Dispensing error, Toxicity",
author = "O'Connor, {Ayrn D.} and Daniel Rusyniak and James Mowry",
year = "2008",
month = "11",
doi = "10.1080/15563650801898528",
language = "English",
volume = "46",
pages = "838--840",
journal = "Clinical Toxicology",
issn = "1556-3650",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - Acute tacrolimus toxicity in a non-transplant patient

AU - O'Connor, Ayrn D.

AU - Rusyniak, Daniel

AU - Mowry, James

PY - 2008/11

Y1 - 2008/11

N2 - Introduction. Tacrolimus is an immunosuppressant widely used in recipients of solid organ transplants to prevent rejection. Toxicity is usually reported in transplant patients. We report the first case of tacrolimus toxicity in a non-transplant patient. Case report. A 42 year-old, 48 kg woman complained of neck pain following a motor vehicle collision and was admitted for observation. On examination, her pulse was 112 beats/minute and her blood pressure 188/134 mmHg. Because the hypertension and tachycardia might be ethanol withdrawal, she was admitted and treated with multivitamins, folate, and thiamine in her maintenance fluids. She was discharged after 4 days in hospital. The day after her discharge, she was asked to return after it was discovered that she had inadvertently received tacrolimus (total of 400 mg) instead of thiamine. She was admitted with non-oliguric renal failure and metabolic acidosis. A tacrolimus concentration 27 hours after her last exposure was 96.8 ng/mL (therapeutic 5 to 20 ng/mL). Treatment was supportive and she was discharged after 4 days without sequellae. Discussion. Our patient's tacrolimus dose was 2.1 mg/kg/day for 4 days (therapeutic 0.03 to 0.05 mg/kg/day). Her tacrolimus elimination half-life was 16.5 hours, compared to a mean half-life in healthy volunteers of 34.2 ± 7.7 hours. Conclusion. Clinical toxicity, similar to that seen in transplant patients, can develop in non-transplant patients following intravenous administration of supra-therapeutic doses of tacrolimus.

AB - Introduction. Tacrolimus is an immunosuppressant widely used in recipients of solid organ transplants to prevent rejection. Toxicity is usually reported in transplant patients. We report the first case of tacrolimus toxicity in a non-transplant patient. Case report. A 42 year-old, 48 kg woman complained of neck pain following a motor vehicle collision and was admitted for observation. On examination, her pulse was 112 beats/minute and her blood pressure 188/134 mmHg. Because the hypertension and tachycardia might be ethanol withdrawal, she was admitted and treated with multivitamins, folate, and thiamine in her maintenance fluids. She was discharged after 4 days in hospital. The day after her discharge, she was asked to return after it was discovered that she had inadvertently received tacrolimus (total of 400 mg) instead of thiamine. She was admitted with non-oliguric renal failure and metabolic acidosis. A tacrolimus concentration 27 hours after her last exposure was 96.8 ng/mL (therapeutic 5 to 20 ng/mL). Treatment was supportive and she was discharged after 4 days without sequellae. Discussion. Our patient's tacrolimus dose was 2.1 mg/kg/day for 4 days (therapeutic 0.03 to 0.05 mg/kg/day). Her tacrolimus elimination half-life was 16.5 hours, compared to a mean half-life in healthy volunteers of 34.2 ± 7.7 hours. Conclusion. Clinical toxicity, similar to that seen in transplant patients, can develop in non-transplant patients following intravenous administration of supra-therapeutic doses of tacrolimus.

KW - Acid-base disorders

KW - Acute renal failure

KW - Dispensing error

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=55949130015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55949130015&partnerID=8YFLogxK

U2 - 10.1080/15563650801898528

DO - 10.1080/15563650801898528

M3 - Article

VL - 46

SP - 838

EP - 840

JO - Clinical Toxicology

JF - Clinical Toxicology

SN - 1556-3650

IS - 9

ER -